Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 58

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 58
---
30, 2025:               |

| • |     | 8,681,079 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted exercise 
 price of $4.61 per share;                                                                                       |

| • |     | 7,521,208 shares of Common Stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity 
 Incentive Plan;                                                                                              |

| • |     | 13,450,711 shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted exercise price 
 of $4.55 per share;                                                                                               |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the                                                 
 Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject             
 to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

S-5

RISK FACTORS

You should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks we are not presently aware of or that we currently believe are immaterial may also impair our business operations, financial condition or results of operations. Our business, financial condition or results of operations could be harmed by any of these risks. The trading price of our Common Stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the risk factors and other information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, specifically including the risk factors contained in our most recent Annual Report on Form 10-Kor Quarterly Report on Form 10-Q,as filed with the SEC, which are incorporated in this prospectus by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any free writing prospectus that we may authorize for use in connection with this offering.

Risks Related to this Offering

Management will have broad discretion as to the use of the net proceeds from this offering, and we